Table 1.

Summary of the anticancer IVM studies.

Reference	Type of Study	Description	Objective	Subtype of Cancer
Draganov et al. [32]	In Vivo	The IVM effects were study using a 4T1 mouse model of TNBC. The results indicate that IVM has dual immunomodulatory and ICD-inducing effects in breast cancer	To evaluate animal line cells	Breast cancer
Dou et al. [29]	In Vivo and In Vitro	The authors report a role for IVM-induced autophagy in breast cancer cells. The results provide a molecular basis for the use of IVM to inhibit the proliferation of breast cancer cells.	To evaluate cellular PAK 1 line	Breast cancer
Zhang et al. [33]	In Vivo and In Vitro	The molecular mechanism and effects of IVM alone and its combination with cisplatin on growth and survival were examined. Results indicate that IVM significantly augmented the inhibitory effect of cisplatin on ovarian cancer cells in a dose-dependent manner.	To evaluate cultured ovarian cancer cells and a xenograft mouse model, focusing on Akt/mTOR signaling	Ovarian cancer
Jiang et al. [34]	In Vivo and In Vitro	The effects of IVM on cancer cells lines which are resistant to the chemotherapeutin drugs vincristine and adriamycin were investigate in vitro. Flow cytometry, immunohistochemistry, and immunofluorescence were used to investigate the reversal effect of IVM in vivo. Results indicated that IVM at its very low dose drastically reversed the resistance of the tumor cells to the chemotherapeutic drugs both in vitro and in vivo.	To evaluate two (HCT-8) colorectal cancer cells and (MCF-7) breast cancer cells), one hematologic tumor (K562) and two xenograft mice models	Colorectal, breast cancer and one hematologic tumor cell line
Zhou et al. [35]	In Vivo	The results demonstrated that ivermectin dose-dependently inhibited colorectal cancer SW480 and SW1116 cell growth, which was followed by promoting cell apoptosis and increasing Caspase-3/7 activity.	To evaluate the influence of ivermectin on CRC using CRC cell lines SW480 and SW1116	Colorectal cancer